Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics.
Ocuphire Pharma Inc. (NASDAQ: OCUP) Highlighted for Surprising Price ActionOcuphire Pharma, Inc. (
NASDAQ: OCUP) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 15.41% on the day to $5.21.
Ocuphire Pharma, Inc. (NASDAQ: OCUP) Featured in Coverage of The MicroCap Rodeo’s 3rd Annual Winter Wonderful and Best Ideas Investor ConferenceOcuphire Pharma (
NASDAQ: OCUP) is a publicly traded, clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders.
60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in ChicagoRALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor audience.
